CloudCath is a Rosenman Innovator company.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in potential complications.

CloudCath’s device analyzes and measures the fluids drained from the abdomens of patients with end-stage renal disease. During a peritoneal dialysis treatment, the wireless system integrates with the drainage line to detect any deviations in the spent dialysate fluid and then notifies healthcare providers.

The San Francisco-based company’s series A round was led by Capital Integral with additional backing from FundRx, The Capital Partnership, Coconut Tree Investments and Stanford University’s StartX Fund as well as additional strategic and individual investors. The proceeds will also support the development of additional applications, according to CloudCath.

Read the full story at Fierce Biotech